banda transcan 2 2016ul

Title: Mutated neo-antigens in hepatocellular carcinoma


Project Coordinator:
Luigi BUONAGURO (Italy) National cancer Institute "Pascale", Department of Experimental Oncology, Napoli


Project Partners:
Danila  VALMORI (France) INSERM U1102 "Cancer Vaccines and Immune Regulation" Institut de Cancerologie de l'Ouest-CLCC René Gauducheau, Saint Herblain
Bruno SANGRO (Spain) Department of Internal Medicine, Hepathology Unit, Universidad de Navarra, Pamplona, Navarra 
Frederic AMANT (Belgium) Oncology Dept. University Hospitals Leuven - KU Leuven
Lucia LOPALCO (Italy) Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele, Milano
Toivo MAIMETS (Estonia) Institute of Molecular and Cell Biology, Competence Centre for Cancer Reaserch, Tallin
Edvins MIKLASEVICS (Latvia) RSU Oncology Institute, Riga


Project Abstract:
Background and rationale: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Immunotherapeutic interventions may help at improving therapeutic outcome in HCC patients. Identification and immunological validation of specific mutated neo-antigens represents an essential knowledge.
Hypothesis: The hypothesis of the present proposal is that identification and immunological validation of mutated neo-antigens specific to HCC will be essential to subsequently develop immunotherapy strategies for improved clinical outcome in HCC patients.
Aims: The primary aim is the identification and immunological validation of mutated neo-antigens specific to HCC. Specific aims will be: 1) evaluate the mutational rate in HCC samples and predict the presentation of neo-epitopes by HLA-A2*01 allele; 2) assess the frequency of specific T cell response to such mutant epitopes in HCC patients, before and after treatment with checkpoint inhibitors (CI); 3) validate the immunogenicity of neo-epitopes in an HLA-transgenic mice and their therapeutic effect in a patient-derived xenograft (PDX) animal model; 4) identify mutated full-length proteins presented on the surface of HCC cancer cells; 5) develop MAbs to such mutated proteins and validate their specificity in vivo in a PDX animal model. Expected results and potential impact: The results of the proposed study will be the identification of HCC-specific target mutated neo-antigens (e.g. epitopes and proteins) and their immuological relevance in a PDX animal model and in HCC patients before and after CI treatment. Such results will have a potential extremely high impact, serving as a foundation for subsequent therapeutic strategies targeting HCC. Mutated neo-antigens will provide a source of immunogens to be used alone or in combination with wild-type antigens identified within the ongoing FP7-funded HEPAVAC project (Coordinator L. Buonaguro). The present HEPAMUT will complement and go far beyond HEPAVAC. 



(Project selected for funding under JTC 2015)


TRANSCAN-2 News


CLOSED CALL

 Fourth Joint Transnational Call 2017 (JTC 2017)

on: Translational Research on Rare Cancers

 Deadline for submission of pre-proposals: February 6th, 2018

visit the page


JTC 2016

on: “Minimally and non-invasive methods for early detection and/or progression of cancer"

14 projects selected for funding 

visit the page


 

Newsletters

Newsletter 6, June 2108

Newsletter 5, March 2018

Newsletter 4, December 2017

Newsletter 3, September 2017

Newsletter 2, April 2017

Newsletter 1, December 2016

To subscribe to TRANSCAN-2 newsletter mailing list please send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.